P/E ratio for Sage Therapeutics (SAGE)
P/E ratio as of May 2024 (TTM): -1.20
According to Sage Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.20464. At the end of 2022 the company had a P/E ratio of -4.25.
P/E ratio history for Sage Therapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.25 | -22.12% |
| 2021 | -5.45 | -173.19% |
| 2020 | 7.45 | -238.11% |
| 2019 | -5.40 | -54.66% |
| 2018 | -11.9 | -48.56% |
| 2017 | -23.1 | 112.94% |
| 2016 | -10.9 | -36.83% |
| 2015 | -17.2 | -22.08% |
| 2014 | -22.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Regulus Therapeutics RGLS | -1.33 | 10.77% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | 2.97 | -346.83% | 🇺🇸 USA |
 Horizon Therapeutics
HZNP | 60.6 | -5,128.30% | 🇮🇪 Ireland |
 Eagle Pharmaceuticals
EGRX | 4.96 | -511.45% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.